Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

InterbrandHealth

- PMLiVE

AZ, Pfizer/BioNTech COVID-19 vaccines ‘highly effective’ against Indian variant

UK study finds vaccines are likely to be effective in preventing hospitalisation/death

- PMLiVE

Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab

Trial will enrol 600 adults, aged 65 and older, from the phase 3 Pfizer/BioNTech COVID-19 vaccine trial

- PMLiVE

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

SGLT2 inhibitor failed to significantly reduce the number of patients who experienced organ failure or died compared to placebo

- PMLiVE

Developers of COVID-19 vaccines and therapeutics highlight continued need for treatments

Continued need for vaccines/treatments 'likely' as world moves into the next phase of the pandemic

- PMLiVE

Pfizer asks UK’s MHRA to approve its COVID-19 vaccine in adolescents

The vaccine has been authorised in the US for 12- to 15-year-olds

- PMLiVE

Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’

Company says removing IP protections would make it ‘harder’ to make vaccines in the short term

- PMLiVE

EU asks AZ to deliver 120 million COVID-19 vaccines by the end of June

The EU has launched a new lawsuit against the drugmaker which could result in financial sanctions

- PMLiVE

AZ, Amgen file first-in-class asthma drug with the FDA

Submission is based on positive results from the companies’ PATHFINDER clinical programme

- PMLiVE

Emergency authorisation for Pfizer/BioNTech vaccine expanded in the US

Data from a study involving 12 to 15 year olds has also been submitted to the EMA for potential approval

- PMLiVE

AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate

Datopotamab deruxtecan shows early promise in heavily pre-treated patient group

- PMLiVE

Pfizer, BioNTech file for full US approval of COVID-19 vaccine

Pfizer chief executive Albert Bourla said last week the company is on track to supply 2.7bn doses in 2021

- PMLiVE

Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

Trial pause follows reports of three cases of peripheral neuropathy in phase 1 study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links